{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:20:49Z","timestamp":1787250049520,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060663, 82260716"],"award-info":[{"award-number":["82060663, 82260716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02337-2","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:05:34Z","timestamp":1751954734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Artificial intelligence-driven discovery of YH395A: A novel TGF\u03b2R1 inhibitor with potent anti-tumor activity against triple-negative breast cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Jun","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"FengSong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"1","key":"2337_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2337_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won KA, Spruck C. Triple\u2013negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245\u201361.","journal-title":"Int J Oncol"},{"issue":"10286","key":"2337_CR3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, et al. Breast cancer. Lancet. 2021;397(10286):1750\u201369.","journal-title":"Lancet"},{"issue":"1","key":"2337_CR4","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2337_CR5","doi-asserted-by":"crossref","unstructured":"Bou Zerdan M et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers (Basel), 2022. 14(5).","DOI":"10.3390\/cancers14051253"},{"key":"2337_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative breast Cancer. Annu Rev Pathol. 2022;17:181\u2013204.","journal-title":"Annu Rev Pathol"},{"key":"2337_CR7","doi-asserted-by":"crossref","unstructured":"Park M et al. Breast Cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci, 2022. 23(12).","DOI":"10.3390\/ijms23126806"},{"key":"2337_CR8","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","volume":"237","author":"JY So","year":"2022","unstructured":"So JY, et al. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:108253.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452\u201378.","journal-title":"J Natl Compr Canc Netw"},{"key":"2337_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"key":"2337_CR11","doi-asserted-by":"publisher","first-page":"115170","DOI":"10.1016\/j.biopha.2023.115170","volume":"165","author":"R Farghadani","year":"2023","unstructured":"Farghadani R, Naidu R. The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC). Biomed Pharmacother. 2023;165:115170.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2337_CR12","first-page":"215","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague J. TGFbeta Cancer Cell. 2008;134(2):215\u201330.","journal-title":"TGFbeta Cancer Cell"},{"key":"2337_CR13","doi-asserted-by":"crossref","unstructured":"Hata A, Chen YG. TGF-beta signaling from receptors to Smads. Cold Spring Harb Perspect Biol, 2016. 8(9).","DOI":"10.1101\/cshperspect.a022061"},{"issue":"6659","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/37284","volume":"390","author":"CH Heldin","year":"1997","unstructured":"Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390(6659):465\u201371.","journal-title":"Nature"},{"issue":"3","key":"2337_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1357-2725(97)00128-3","volume":"30","author":"DA Clark","year":"1998","unstructured":"Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol. 1998;30(3):293\u20138.","journal-title":"Int J Biochem Cell Biol"},{"key":"2337_CR16","doi-asserted-by":"crossref","unstructured":"Morikawa M, Derynck R, Miyazono K. TGF-beta and the TGF-beta family: Context-Dependent roles in cell and tissue physiology. Volume 8. Cold Spring Harb Perspect Biol; 2016. 5.","DOI":"10.1101\/cshperspect.a021873"},{"key":"2337_CR17","doi-asserted-by":"crossref","unstructured":"Baj J et al. Mechanisms of the Epithelial-Mesenchymal transition and tumor microenvironment in Helicobacter pylori-Induced gastric Cancer. Cells, 2020. 9(4).","DOI":"10.3390\/cells9041055"},{"issue":"11","key":"2337_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00018-019-03398-6","volume":"77","author":"W Hua","year":"2020","unstructured":"Hua W, et al. TGFbeta-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77(11):2103\u201323.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2337_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12929-020-00632-3","volume":"27","author":"YT Lin","year":"2020","unstructured":"Lin YT, Wu KJ. Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-beta signaling. J Biomed Sci. 2020;27(1):39.","journal-title":"J Biomed Sci"},{"key":"2337_CR20","doi-asserted-by":"crossref","unstructured":"Pallasch FB, Schumacher U. Angiotensin inhibition, TGF-beta and EMT in Cancer. Cancers (Basel), 2020. 12(10).","DOI":"10.3390\/cancers12102785"},{"issue":"1","key":"2337_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P. Targeting TGF-beta signaling in Cancer. Trends Cancer. 2017;3(1):56\u201371.","journal-title":"Trends Cancer"},{"key":"2337_CR22","doi-asserted-by":"crossref","unstructured":"Miyazawa K, Miyazono K. Regulation of TGF-beta family signaling by inhibitory Smads. Cold Spring Harb Perspect Biol, 2017. 9(3).","DOI":"10.1101\/cshperspect.a022095"},{"issue":"1\u20132","key":"2337_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2005.09.006","volume":"17","author":"B Bierie","year":"2006","unstructured":"Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev. 2006;17(1\u20132):29\u201340.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"2337_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.biocel.2007.09.006","volume":"40","author":"S Ross","year":"2008","unstructured":"Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008;40(3):383\u2013408.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"2337_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.devcel.2009.01.022","volume":"16","author":"F Dai","year":"2009","unstructured":"Dai F, et al. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. Dev Cell. 2009;16(3):345\u201357.","journal-title":"Dev Cell"},{"issue":"6400","key":"2337_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.aat2663","volume":"361","author":"B Sanchez-Lengeling","year":"2018","unstructured":"Sanchez-Lengeling B, Aspuru-Guzik A. Inverse molecular design using machine learning: generative models for matter engineering. Science. 2018;361(6400):360\u20135.","journal-title":"Science"},{"issue":"10","key":"2337_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1021\/acs.accounts.4c00093","volume":"57","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. Advancing ligand Docking through deep learning: challenges and prospects in virtual screening. Acc Chem Res. 2024;57(10):1500\u20139.","journal-title":"Acc Chem Res"},{"issue":"11","key":"2337_CR28","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1021\/acs.jctc.1c00810","volume":"17","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. Efficient exploration of chemical space with Docking and deep learning. J Chem Theory Comput. 2021;17(11):7106\u201319.","journal-title":"J Chem Theory Comput"},{"issue":"10","key":"2337_CR29","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1021\/acs.jcim.1c00608","volume":"61","author":"L Hu","year":"2021","unstructured":"Hu L, et al. Kinase inhibitor scaffold hopping with deep learning approaches. J Chem Inf Model. 2021;61(10):4900\u201312.","journal-title":"J Chem Inf Model"},{"key":"2337_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-0716-1787-8_11","volume":"2390","author":"A Anighoro","year":"2022","unstructured":"Anighoro A. Deep learning in Structure-Based drug design. Methods Mol Biol. 2022;2390:261\u201371.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2337_CR31","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1038\/s41467-022-34692-w","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor. Nat Commun. 2022;13(1):6891.","journal-title":"Nat Commun"},{"issue":"1","key":"2337_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/acs.jmedchem.3c02102","volume":"67","author":"L Zhang","year":"2024","unstructured":"Zhang L, et al. From hit to lead: Structure-Based optimization of novel selective inhibitors of Receptor-Interacting protein kinase 1 (RIPK1) for the treatment of inflammatory diseases. J Med Chem. 2024;67(1):754\u201373.","journal-title":"J Med Chem"},{"issue":"1","key":"2337_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djs485","volume":"105","author":"Y Fang","year":"2013","unstructured":"Fang Y, et al. Inhibition of breast cancer metastases by a novel inhibitor of TGFbeta receptor 1. J Natl Cancer Inst. 2013;105(1):47\u201358.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2337_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/jm401117t","volume":"57","author":"C Zheng","year":"2014","unstructured":"Zheng C, et al. Synthesis and biological evaluation of novel tetrahydro-beta-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-beta signaling pathway. J Med Chem. 2014;57(3):600\u201312.","journal-title":"J Med Chem"},{"key":"2337_CR35","doi-asserted-by":"crossref","unstructured":"Sulaiman A et al. Clinically translatable approaches of inhibiting TGF-beta to target Cancer stem cells in TNBC. Biomedicines, 2021. 9(10).","DOI":"10.3390\/biomedicines9101386"},{"key":"2337_CR36","doi-asserted-by":"publisher","first-page":"772296","DOI":"10.3389\/fphar.2021.772296","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. An integrated deep learning and molecular dynamics Simulation-Based screening pipeline identifies inhibitors of a new Cancer drug target TIPE2. Front Pharmacol. 2021;12:772296.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2337_CR37","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2174\/138920111798377102","volume":"12","author":"LR Gomes","year":"2011","unstructured":"Gomes LR, et al. Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr Pharm Biotechnol. 2011;12(11):1881\u201390.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"2337_CR38","doi-asserted-by":"publisher","first-page":"9909","DOI":"10.1038\/s41467-024-54400-0","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, et al. High mobility group A1 (HMGA1) promotes the tumorigenesis of colorectal cancer by increasing lipid synthesis. Nat Commun. 2024;15(1):9909.","journal-title":"Nat Commun"},{"key":"2337_CR39","doi-asserted-by":"publisher","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.","journal-title":"Pharmacol Res"},{"key":"2337_CR40","doi-asserted-by":"crossref","unstructured":"Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells, 2020. 9(10).","DOI":"10.3390\/cells9102308"},{"issue":"2","key":"2337_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.gastro.2021.04.064","volume":"161","author":"NR Gough","year":"2021","unstructured":"Gough NR, Xiang X, Mishra L. TGF-beta signaling in liver, pancreas, and Gastrointestinal diseases and Cancer. Gastroenterology. 2021;161(2):434\u2013e45215.","journal-title":"Gastroenterology"},{"issue":"4S","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jid.2020.11.007","volume":"141","author":"Y Ke","year":"2021","unstructured":"Ke Y, Wang XJ. TGFbeta signaling in Photoaging and UV-Induced skin Cancer. J Invest Dermatol. 2021;141(4S):1104\u201310.","journal-title":"J Invest Dermatol"},{"key":"2337_CR43","doi-asserted-by":"publisher","first-page":"107666","DOI":"10.1016\/j.pharmthera.2020.107666","volume":"217","author":"BA Teicher","year":"2021","unstructured":"Teicher BA. TGFbeta-Directed therapeutics: 2020. Pharmacol Ther. 2021;217:107666.","journal-title":"Pharmacol Ther"},{"key":"2337_CR44","doi-asserted-by":"publisher","first-page":"155709","DOI":"10.1016\/j.cyto.2021.155709","volume":"148","author":"J Wang","year":"2021","unstructured":"Wang J, et al. TGF-beta signaling in cancer radiotherapy. Cytokine. 2021;148:155709.","journal-title":"Cytokine"},{"key":"2337_CR45","doi-asserted-by":"publisher","first-page":"114716","DOI":"10.1016\/j.biopha.2023.114716","volume":"162","author":"JE Lee","year":"2023","unstructured":"Lee JE, et al. Vactosertib, TGF-beta receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Biomed Pharmacother. 2023;162:114716.","journal-title":"Biomed Pharmacother"},{"key":"2337_CR46","doi-asserted-by":"crossref","unstructured":"Yun KH et al. Therapeutic implications of TGF-beta pathway in desmoid tumor based on comprehensive molecular profiling and clinicopathological properties. Cancers (Basel), 2022. 14(23).","DOI":"10.3390\/cancers14235975"},{"issue":"9","key":"2337_CR47","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022;23(9):1189\u2013200.","journal-title":"Lancet Oncol"},{"key":"2337_CR48","doi-asserted-by":"crossref","unstructured":"Wick W, Weller M et al. Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn. (Neuro-Oncology 2011;13:132\u2013142). Neuro Oncol, 2011. 13(5): pp. 559\u2013\u200960; author reply 561-2.","DOI":"10.1093\/neuonc\/nor047"},{"issue":"7","key":"2337_CR49","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in Second-Line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thorac Oncol. 2020;15(7):1210\u201322.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2337_CR50","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1172\/JCI94624","volume":"127","author":"Y Wei","year":"2017","unstructured":"Wei Y, et al. Fibroblast-specific Inhibition of TGF-beta1 signaling attenuates lung and tumor fibrosis. J Clin Invest. 2017;127(10):3675\u201388.","journal-title":"J Clin Invest"},{"issue":"4","key":"2337_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massague J. Transforming growth Factor-beta signaling in immunity and Cancer. Immunity. 2019;50(4):924\u201340.","journal-title":"Immunity"},{"issue":"1","key":"2337_CR52","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13046-021-02164-6","volume":"40","author":"C Wang","year":"2021","unstructured":"Wang C, et al. Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer. J Exp Clin Cancer Res. 2021;40(1):370.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2337_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40169-018-0205-6","volume":"7","author":"W Chen","year":"2018","unstructured":"Chen W, Qin Y, Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Transl Med. 2018;7(1):27.","journal-title":"Clin Transl Med"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02337-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:41:50Z","timestamp":1757209310000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02337-2","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical samples used in this study were approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (No. ZE2020-334-01). Animal experiments in this study were approved by the Ethics Committee of Ningxia Medical University (No. IACUC-NYLAC-2022-015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"326"}}